Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPINOZA: Obicetrapib in Preclinical Alzheimer's Disease
NCT07794670Phase 2Recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Placebo with Obicetrapib (2 arms). Primary endpoint: Phosphorylated Tau 217 at 52 weeks. Started Sep 2026; status: recruiting.
02
Drugs
obicetrapib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07794670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07794670.